Eugenyl acetate, also called acetyl eugenol, is the characteristic secondary phenylpropanoid ester of clove bud oil and a recurring minor constituent of cinnamon leaf and related spice profiles. The live evidence base is mixed but usable: identity and occurrence are straightforward, a modern RIFM safety assessment is publicly accessible, and several older or mid-2010s papers report platelet, anti-virulence, antimicrobial, or antioxidant effects in laboratory systems. AromaForge should therefore frame eugenyl acetate as a clove-marker constituent with some direct preclinical activity data and a stronger safety profile than its standalone human-evidence base.
Chemical identity and composition
PubChem and NIST identify eugenyl acetate as C12H14O3 with InChIKey SCCDQYPEOIRVGX-UHFFFAOYSA-N. NIST lists synonyms including aceteugenol, acetyleugenol, eugenol acetate, and eugenyl acetate. The 2020 RIFM safety assessment emphasizes that this ester is rapidly hydrolyzed to eugenol and acetic acid, which matters for interpreting both safety read-across and mechanism claims.
Aroma and practical use
- Use the recorded sweet clove, spicy, balsamic, warmer and softer than eugenol descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The 2020 RIFM assessment concluded that eugenyl acetate was not expected to be genotoxic, reported a repeated-dose NOAEL of 500 mg/kg/day, and stated that it was not expected to be phototoxic or photoallergenic under assessed use conditions.
RIFM also reported no current skin-sensitization concern at declared use levels and used hydrolysis plus read-across logic for developmental and reproductive endpoints.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A 2015 Antonie van Leeuwenhoek paper reported that eugenyl acetate at 150 microg/mL reduced multiple virulence outputs in Pseudomonas aeruginosa and Staphylococcus aureus, and at 75 microg/mL inhibited violacein production in Chromobacterium violaceum.
This is one of the clearest constituent-level studies suggesting quorum-sensing or virulence-modulating activity, but it remains an in vitro microbiology result.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 1991 platelet study reported that acetyl eugenol abolished arachidonate-induced platelet aggregation at about 12 microM and linked the effect to reduced thromboxane formation with increased 12-HPETE generation.
Because the study used human blood platelets and biochemical endpoints, it is stronger than a purely speculative mechanism note, but it still does not establish clinical antiplatelet use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2014 Applied Biochemistry and Biotechnology study found that enzymatically produced eugenyl acetate retained antioxidant potential but showed lower antibacterial activity than the original clove essential oil in the tested system.
This is useful because it helps separate eugenyl acetate from whole-oil assumptions and suggests esterification can shift biological behavior rather than simply preserve the parent clove profile.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedRIFM reported no skin-sensitization concern for eugenyl acetate at current declared fragrance-use levels despite the molecule's structural alert and despite its hydrolysis relationship to eugenol.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
RIFM evaluated eugenyl acetate as not expected to be phototoxic or photoallergenic based on UV/Vis spectra and supporting assessment logic.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because eugenyl acetate can hydrolyze to eugenol, safety interpretation should not ignore parent-metabolite overlap even when the ester itself appears less sensitization-active in the reviewed tests.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · whole_oil
No source citation attached.
Read Eugenol report →(E)-CaryophylleneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · whole_oil
No source citation attached.
Read (E)-Caryophyllene report →How the effects were investigated
rapid ester hydrolysis to eugenol and acetic acid
RIFM cites microsomal hydrolysis data indicating that eugenyl acetate is rapidly and substantially converted to eugenol, so some downstream toxicology and possibly some biological effects may converge with eugenol chemistry.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
virulence-factor and quorum-sensing interference in bacterial models
A 2015 pathogenic-bacteria study reported reduced pyocyanin, pyoverdin, protease, haemolytic activity, staphyloxanthin, and violacein outputs under tested eugenyl acetate conditions, consistent with anti-virulence rather than simple bactericidal framing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No strong isolated-compound human efficacy literature for eugenyl acetate was verified in this pass.
- Several accessible activity papers are in vitro or ex vivo and do not clarify whether observed effects would persist after topical or oral metabolism to eugenol.
- The public safety record is better than the public clinical record, so archive language should stay chemistry-forward and cautious.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.